Refine your search:     
Report No.

Application of PET imaging with $$^{64}$$Cu for quantitative evaluation of radioimmunotherapy

Iida, Yasuhiko*; Hanaoka, Hirofumi*; Katabuchi, Tatsuya*; Watanabe, Satoshi; Ishioka, Noriko; Matsuhashi, Shimpei; Oriuchi, Noboru*; Higuchi, Tetsuya*; Miyakubo, Mitsuyuki*; Endo, Keigo*

$$^{64}$$Cu is one of the most attractive candidate emitter for radioimmunotherapy (RIT). $$^{64}$$Cu releases positron emitter (0.653 MeV, 18%) as well as middle energy $$beta$$-particles (0.578 MeV, 37%), so it can be applied for diagnostic imaging with PET. PET is superior in quantitative measurement and suitable for evaluation of therapeutic effect with RIT. PET can also directly estimate radiation dose of RIT. In this study, we prepared a radioimmunoconjugate, NuB2, anti-CD20 monoclonal antibody (mAb), labeled with $$^{64}$$Cu, and evaluated its potential for PET imaging with RIT. NuB2 was labeled with $$^{64}$$Cu. For in vivo studies, SCID mice bearing CD20$$^{+}$$ tumor were used. After administration, biodistribution and PET imaging were performed. For the results of biodistribution, $$^{64}$$Cu-NuB2 was highly accumulated to CD20$$^{+}$$ tumor, and PET images could show the same results. From these date, the use of $$^{64}$$Cu for PET imaging has potential for accurately evaluation of therapeutic effect of RIT.



- Accesses





[CLARIVATE ANALYTICS], [WEB OF SCIENCE], [HIGHLY CITED PAPER & CUP LOGO] and [HOT PAPER & FIRE LOGO] are trademarks of Clarivate Analytics, and/or its affiliated company or companies, and used herein by permission and/or license.